A periwinkle-derived compound used for decades abroad to treat poor brain circulation and sold in the United States as a memory supplement. It widens small brain vessels and improves brain energy use. Its clearest human benefit is reduced disability when given early after a circulation-type stroke; cognitive gains in healthy people stay weak and unproven, with safety and quality concerns. (Full Review)

Protocol

Dose

5–10 mg 3×/day

15–30 mg/day total in divided doses

Titration

Start low

Begin 5 mg 2–3×/day; increase toward 10 mg 3×/day if tolerated

Timing

Divided dosing

Morning, midday, early evening; last dose away from bedtime

Time to effect

Blood flow

Hours

Acute increase in cerebral blood flow

Cognitive/symptom benefit

Weeks

Emerges over weeks of consistent use, where it occurs

Trial window

8–12 weeks

Reasonable trial to judge whether benefit occurs

Benefits

Medium: Reduced disability after acute ischemic stroke; enhanced cerebral blood flow and glucose uptake

Low: Modest support in vascular cognitive impairment; relief of chronic cerebrovascular symptoms

Speculative: Anti-inflammatory and anti-atherosclerotic effects; sensorineural hearing preservation; metabolic and anti-adipogenic effects

Contraindications

Pregnancy, breastfeeding, or possible pregnancy

Bleeding disorders or full-dose anticoagulation (e.g., therapeutic warfarin, high INR)

Surgery scheduled within ~2 weeks

Clinically low blood pressure

History of low white-cell or platelet counts

Key Interactions

Anticoagulants/antiplatelets (warfarin, clopidogrel, apixaban)

Blood-pressure-lowering drugs (ACE inhibitors, calcium channel blockers, beta-blockers)

Antiarrhythmic and vasoactive drugs

Aspirin and NSAIDs (ibuprofen, naproxen)

Blood-thinning supplements (fish oil, ginkgo, garlic, vitamin E, nattokinase)

Blood-pressure-lowering supplements (magnesium, potassium, CoQ10, beetroot/nitrate)

Alcohol

Risk & Side Effects

High: Reproductive and fetal harm; gastrointestinal upset

Medium: Blood-pressure lowering and flushing; increased bleeding tendency; headache, dizziness, and sleep disturbance

Low: Blood-count and immune effects

Speculative: Unknown long-term safety and unregulated product quality

Monitoring

Marker	Target	Why
Blood pressure	~110–125 / 70–80 mmHg	Detects additive blood-pressure lowering
Complete blood count (CBC)	White cells ~4.0–10.0 ×10⁹/L; platelets ~200–400 ×10⁹/L	Screens for the rare white-cell/platelet suppression
Prothrombin time / INR (if on warfarin)	INR within the individual's target (often 2.0–3.0)	Detects additive bleeding risk from antiplatelet effect
Resting heart rate	~55–70 bpm	Context for vascular/circulatory tolerance
Cognitive/symptom measure (e.g., MoCA)	Stable or improved from baseline	Defines whether the target benefit is actually occurring

Cadence: Baseline; blood pressure and symptoms at 2–4 weeks and after dose changes, then every 3–6 months; CBC every 6–12 months for long-term use

Qualitative Assessment

Subjective mental clarity, focus, and memory in daily tasks
Frequency and severity of circulation-related symptoms (dizziness, vertigo, tinnitus)
Energy levels and absence of new headaches or lightheadedness
Sleep quality, watching for any dosing-related disruption

Vinpocetine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment